RecruitingNCT06008691
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
Studying Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Marco Ladetto, Prof.AO SS Antonio e Biagio e Cesare Arrigo, Alessandria
- Intervention
- "novel" MAB (alone or in combination)(drug)
- Enrollment
- 1500 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2038
Study locations (30)
- Istituto Oncologico del Mediterraneo SPA - Oncologico, Viagrande, Catania, Italy
- Ospedale SS. Cosma e Damiano - Ospedale San Jacopo - SOS Oncoematologia ed ematologia clinica, Pescia, Pistoia, Italy
- A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy
- AOU Ospedali Riuniti - Clinica di Ematologia, Ancona, Italy
- Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico, Avellino, Italy
- IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati, Aviano, Italy
- IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia, Bari, Italy
- Ospedale "Monsignor Raffaele Dimiccoli" - Ematologia, Barletta, Italy
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia, Bergamo, Italy
- Nuovo Ospedale degli Infermi - SSD Ematologia, Biella, Italy
- Policlinico S. Orsola-Malpighi - Istituto di Ematologia "Seragnoli", Bologna, Italy
- ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy
- Ospedale Businco - SC Ematologia e CTMO, Cagliari, Italy
- Fondazione del Piemonte per l'Oncologia - IRCCS - Ematologia, Candiolo, Italy
- Osp. civile di Carrara - Oncologia Medica, Carrara, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
Roche Pharma AG
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06008691 on ClinicalTrials.govOther trials for Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07003295Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT06875063GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHLThe First Affiliated Hospital of Xiamen University
- RECRUITINGNANCT07211048Anti CD19 Gene Therapy for B-cell LymphomaAnhui Provincial Hospital
- RECRUITINGPHASE1NCT07456371PIC1 Injection Therapy for Relapsed/Refractory B-NHLChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07147621Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological MalignanciesUniversity Hospital, Angers
- RECRUITINGNCT07546188AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.Grand Hôpital de Charleroi
- RECRUITINGNCT07253129Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGNCT07374068Prognostic Model of Elderly Hodgkin Lymphoma in ChinaTianjin Medical University Cancer Institute and Hospital